# US 2017/0281567 A1 · Combinations of lsd1 inhibitors for use in the treatment of solid tumors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281567 A1
- Document ID: US20170281567A1
- Status: Published application
- Kind: A1
- Application number: 15/458,640
- Filed: 2017-03-14
- Published: 2017-10-05
- Earliest claimed: 2016-03-15
- Assignees: Hoffmann-La Roche Inc.
- Applicants: Hoffmann-La Roche Inc.
- Inventors: Mark D. DEMARIO; Tamara MAES; William E. PIERCEALL; Fiona MACK; Serena LUNARDI
- Web page: https://patentgrep.com/patent/US20170281567A1

## CPC

- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/12: Ketones
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/282: Platinum compounds
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 31/4402: only substituted in position 2, e.g. pheniramine, bisacodyl
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/475: having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine (vincamine A61K31/4375)
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/52: Purines, e.g. adenine
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 31/635: having a heterocyclic ring, e.g. sulfadiazine
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The instant invention relates to therapeutic combinations of LSD1 inhibitors and one or more other active pharmaceutical ingredient(s) or pharmaceutically acceptable salts thereof. The combinations are particularly useful for treating neoplastic diseases, such as cancer, particularly small cell lung cancer (SCLC).

## Claims

### Claim 1

A therapeutic combination comprising an LSD1 inhibitor or a pharmaceutically acceptable salt thereof, and one or more active pharmaceutical ingredients selected from BCL2 inhibitors, BET inhibitors, EZH2 inhibitors, DOT1L inhibitors, Chk inhibitors, DNA alkylating agents, HDAC inhibitors, topoisomerase inhibitors, anti-mitotic agents, Aurora kinase inhibitors and pharmaceutically acceptable salts thereof.

### Claim 2

A therapeutic combination comprising an LSD1 inhibitor or a pharmaceutically acceptable salt thereof, and one or more active pharmaceutical ingredients selected from the list of ABT-199, ABT-263, ABT-737, ABT-888, ACY-1215, Belinostat, Bendamustine, BGJ398, BMS-906024, Carboplatin, CGK 733, Cisplatin, CPI-169, CPI-203, Docetaxel, Doxorubicin, EPZ-004777, EPZ005687, EPZ-5676, EPZ-6438, Erlotinib, Etoposide, FLI 06, Fluorouracil, GDC-0449, Gemcitabine, GSK126, GSK1324726A, GSK343, GSK-J1, GSK1210151A, Irinotecan, (+)-JQ1, Lapatinib, LDE225, LY2603618, LY-3039478, Menadione, Methotrexate, MK-0752, MLN8237, MS 436, Nutlin-3A, Obatoclax, OTX015, Paclitaxel, Panobinostat, Pemetrexed, PF-04217903, PF-3084014, SAHA, SGC 0946, SNDX-275, Taladegib, Temozolomide, Topotecan, TW-37, Vincristine and pharmaceutically acceptable salts thereof.

### Claim 3 (depends on 1, 2)

The therapeutic combination according to claim 1 or 2 comprising an LSD1 inhibitor or a pharmaceutically acceptable salt thereof and one BCL2 inhibitor or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1, 2)

The therapeutic combination according to claim 1 or 2 comprising an LSD1 inhibitor or a pharmaceutically acceptable salt thereof and one BCL2 inhibitor selected from the list of ABT-199, ABT-263, ABT-737, Obatoclax, TW-37 and a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1, 2)

The therapeutic combination according to claim 1 or 2 comprising an LSD1 inhibitor or a pharmaceutically acceptable salt thereof and one BET inhibitor or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1, 2)

The therapeutic combination according to claim 1 or 2 comprising an LSD1 inhibitor or a pharmaceutically acceptable salt thereof and one BET inhibitor selected from the list of CPI-203, GSK1324726A, GSK1210151A, (+)-JQ1, MS 436, OTX015 and a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1, 2)

The therapeutic combination according to claim 1 or 2 comprising an LSD1 inhibitor or a pharmaceutically acceptable salt thereof and one EZH2 inhibitor or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 1, 2)

The therapeutic combination according to claim 1 or 2 comprising an LSD1 inhibitor or a pharmaceutically acceptable salt thereof and one EZH2 inhibitor selected from the list of CPI-169, EPZ005687, EPZ-6438, GSK126, GSK343 and a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 1, 2)

The therapeutic combination according to claim 1 or 2 comprising an LSD1 inhibitor or a pharmaceutically acceptable salt thereof and one DOT1L inhibitor or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 1, 2)

The therapeutic combination according to claim 1 or 2 comprising an LSD1 inhibitor or a pharmaceutically acceptable salt thereof and one DOT1L inhibitor selected from the list of EPZ-004777, EPZ-5676, SGC 0946 and a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 1, 2)

The therapeutic combination according to claim 1 or 2 comprising an LSD1 inhibitor or a pharmaceutically acceptable salt thereof and one Chk inhibitor or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 1, 2)

The therapeutic combination according to claim 1 or 2 comprising an LSD1 inhibitor or a pharmaceutically acceptable salt thereof and one Chk inhibitor selected from LY2603618 and a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 1, 2)

The therapeutic combination according to claim 1 or 2 comprising an LSD1 inhibitor or a pharmaceutically acceptable salt thereof and one DNA alkylating agent or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 1, 2)

The therapeutic combination according to claim 1 or 2 comprising an LSD1 inhibitor or a pharmaceutically acceptable salt thereof and one DNA alkylating agent selected from the list of Bendamustine, Carboplatin, Cisplatin, Temozolomide and a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 1, 2)

The therapeutic combination according to claim 1 or 2 comprising an LSD1 inhibitor or a pharmaceutically acceptable salt thereof and one HDAC inhibitor or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 1, 2)

The therapeutic combination according to claim 1 or 2 comprising an LSD1 inhibitor or a pharmaceutically acceptable salt thereof and one HDAC inhibitor selected from the list of ACY-1215, Belinostat, Panobinostat, SAHA, SNDX-275 and a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 1, 2)

The therapeutic combination according to claim 1 or 2 comprising an LSD1 inhibitor or a pharmaceutically acceptable salt thereof and one topoisomerase inhibitor or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 1, 2)

The therapeutic combination according to claim 1 or 2 comprising an LSD1 inhibitor or a pharmaceutically acceptable salt thereof and one topoisomerase inhibitor selected from the list of Etoposide, Irinotecan, Topotecan and a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 1, 2)

The therapeutic combination according to claim 1 or 2 comprising an LSD1 inhibitor or a pharmaceutically acceptable salt thereof and one Aurora kinase inhibitor or a pharmaceutically acceptable salt thereof.

### Claim 20 (depends on 1, 2)

The therapeutic combination according to claim 1 or 2 comprising an LSD1 inhibitor or a pharmaceutically acceptable salt thereof and one Aurora kinase inhibitor selected from the list of MLN8237 and a pharmaceutically acceptable salt thereof.

### Claim 21 (depends on 1, 2)

The therapeutic combination according to claim 1 or 2 comprising an LSD1 inhibitor or a pharmaceutically acceptable salt thereof and one anti-mitotic agent or a pharmaceutically acceptable salt thereof.

### Claim 22 (depends on 1, 2)

The therapeutic combination according to claim 1 or 2 comprising an LSD1 inhibitor or a pharmaceutically acceptable salt thereof and one anti-mitotic agent selected from the list of Docetaxel, Paclitaxel, Vincristine and a pharmaceutically acceptable salt thereof.

### Claim 23 (depends on 1, 2)

The therapeutic combination according to claim 1 or 2 comprising an LSD1 inhibitor or a pharmaceutically acceptable salt thereof, a topoisomerase inhibitor or a pharmaceutically acceptable salt thereof, and a DNA alkylating agent or a pharmaceutically acceptable salt thereof.

### Claim 24 (depends on 1, 2)

The therapeutic combination according to claim 1 or 2 comprising an LSD1 inhibitor or a pharmaceutically acceptable salt thereof, Etoposide or a pharmaceutically acceptable salt thereof, and Carboplatin or a pharmaceutically acceptable salt thereof.

### Claim 25 (depends on 1, 2)

The therapeutic combination according to claim 1 or 2, wherein the LSD1 inhibitor is selected from the list of:
4-[[4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]-1-piperidinyl]methyl]-benzoic acid (trans)-N1-((1R,2S)-2-phenylcyclopropyl)cyclohexane-1,4-diamine,
(R)-1-(4-(((trans)-2-phenylcyclopropyl)amino)cyclohexyl)pyrrolidin-3-amine,
4-(aminomethyl)-N-((trans)-2-phenylcyclopropyl)cyclohexanamine,
N1-((trans)-2-phenylcyclopropyl)cyclohexane-1,3-diamine,
N1-((trans)-2-phenylcyclopropyl)cyclobutane-1,3-diamine,
N1-((trans)-2-phenylcyclopropyl)-2,3-dihydro-1H-indene-1,3-diamine,
N1-methyl-N4-((trans)-2-phenylcyclopropyl)cyclohexane-1,4-diamine,
N1-((trans)-2-(4-bromophenyl)cyclopropyl)cyclohexane-1,4-diamine,
N1-(2-(o-tolyl)cyclopropyl)cyclohexane-1,4-diamine,
N1-(2-(4-methoxyphenyl)cyclopropyl)cyclohexane-1,4-diamine,
N1-(2-(2-fluorophenyl)cyclopropyl)cyclohexane-1,4-diamine,
N1-(2-(naphthalen-2-yl)cyclopropyl)cyclohexane-1,4-diamine,
N-(4′-((trans)-2-((4-aminocyclohexyl)amino)cyclopropyl)-[1,1′-biphenyl]-3-yl)-2-cyanobenzenesulfonamide, and
N1-((trans)-2-(4-(pyridin-3-ylmethoxy)phenyl)cyclopropyl)cyclohexane-1,4-diamine,
or a pharmaceutically acceptable salt thereof.

### Claim 26 (depends on 25)

The therapeutic combination according to claim 25, wherein the LSD1 inhibitor is (trans)-N1-((1R,2S)-2-phenylcyclopropyl)cyclohexane-1,4-diamine or a pharmaceutically acceptable salt thereof.

### Claim 27 (depends on 1, 2)

A pharmaceutical composition comprising a therapeutic combination according to claim 1 or 2 and one or more pharmaceutically acceptable excipients.

### Claim at position 28

28-30. (canceled)

### Claim 31 (depends on 1, 2)

A method for the treatment of a neoplastic disease, which method comprises administering an effective amount of a therapeutic combination according to claim 1 or 2 to a human being or animal.

### Claim 32 (depends on 1, 2)

A method for the treatment of a neoplastic disease, which method comprises sensitizing through administration of an LSD1 inhibitor followed by administering an effective amount of a therapeutic combination according to claim 1 or 2 to a human being or animal.

### Claim 33 (depends on 1, 2)

A method for the treatment of a neoplastic disease, which method comprises sensitizing through administration of (trans)-N1-((1R,2S)-2-phenylcyclopropyl)cyclohexane-1,4-diamine, or a pharmaceutically acceptable salt thereof, followed by administering an effective amount of a therapeutic combination according to claim 1 or 2 to a human being or animal.

### Claim at position 32

34-35. (canceled)

### Claim 36 (depends on 31)

The method of claim 31, wherein the neoplastic disease is a cancer.

### Claim 37 (depends on 31)

The method of claim 31, wherein the neoplastic disease is breast cancer, prostate cancer, cervical cancer, ovarian cancer, gastric cancer, colorectal cancer, pancreatic cancer, liver cancer, brain cancer, neuroendocrine cancer, lung cancer, kidney cancer, hematological malignancies, melanoma and sarcomas.

### Claim 38 (depends on 31)

The method of claim 31, wherein the neoplastic disease is a solid tumor.

### Claim 39 (depends on 31)

The method of claim 31, wherein the neoplastic disease is small cell lung cancer (SCLC).

### Claim 40

(canceled)
